Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Trends in disease focus of drug development

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The top 40 therapeutic/disease areas ranked by the number of trials registered with ClinicalTrials.gov from October 2005 to September 2007.

References

  1. De Angelis C. et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N. Engl. J. Med. 351, 1250–1251 (2004).

    Article  Google Scholar 

  2. De Angelis, C. et al. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. N. Engl. J. Med. 352, 2436–2438 (2005).

    Article  CAS  Google Scholar 

  3. Karlberg, J. P. E. Globalization of sponsored clinical trials. Nature Rev. Drug Discov. 1 May 2008 (doi:10.1038/nrd2441-c1).

    Article  Google Scholar 

  4. Thiers, F. A., Sinskey, A. J. & Berndt, E. R. Trends in the globalization of clinical trials. Nature Rev. Drug Discov. 7, 13–14 (2008).

    Article  CAS  Google Scholar 

  5. Heron, M. Deaths: leading causes for 2004. Natl Vital Stat. Rep. 56, 1–96 (2007).

    PubMed  Google Scholar 

  6. IMS Health. Leading Therapy Classes by Global Pharmaceutical sales, 2006. IMS Health web site [online], (2007).

  7. US Cancer Statistics Working Group. United States Cancer Statistics: 2004 Incidence and Mortality. [online], (2007).

  8. IMS Health. Leading products by Global Pharmaceutical Sales, 2006. IMS Health web site [online], (2007).

  9. Narayan, K. M. V. et al. Lifetime risk for diabetes mellitus in the United States. JAMA 290, 1884–1990 (2003).

    Article  CAS  Google Scholar 

  10. Mokdad, A. H. et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289, 76–79 (2003).

    Article  Google Scholar 

  11. Melnikova, I. & Wages, D. Anti-obesity therapies. Nature Rev. Drug Discov. 5, 369–370 (2006).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study could not have been completed without the implementation of the International Committee of Medical Journal Editors policy and the existence of the ClinicalTrials.gov clinical trials register.

Author information

Authors and Affiliations

Authors

Supplementary information

Supplementary information S1 (box)

Analysis set and analysis (PDF 98 kb)

Supplementary information S2 (table)

Ranking of the top 40 therapeutic/disease areas (PDF 191 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karlberg, J. Trends in disease focus of drug development. Nat Rev Drug Discov 7, 639–640 (2008). https://doi.org/10.1038/nrd2618

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2618

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing